31 Mar FARMAMONDO signs an Exclusivity Agreement with Curefini
FarmaMondo SA and Rev-Pharma, a US bases pharmaceutical company, announce a Global
Early Access program targeted to facilitate access to therapy for patient group suffering from
an Ultra Rare dermatology disease.
Curefini® dermal ointment is intended for improving the Dermatology Quality of Life (DQL) of
patients with various skin disorders.
It has been successfully relieved symptoms of mild and severe skin conditions.
Curefini® dermal ointment works by temporarily protecting injured or exposed skin or mucous
membrane surfaces from harmful or annoying stimuli and may provide relief to such surfaces.
Farmamondo will provide exclusive access to this medication for patients globally (excluding
US, Peru, Brazil, Argentina and Uruguay where product is registered or under registration) via
a model of early access whereas product will be stored in our facility and dispatched
according to the demand.
For all inquiries regarding Curefini® dermal ointment ®, please contact: Rachele Cescutti –
Program Manager, Curefini® dermal ointment, Global Access.
Phone: +41 91 6976392
About Rev Pharma: Rev Pharma is a US based Pharmaceutical company dedicated for the research
and development of therapies to support patients with Epidermolysis bullosa (EB) – a group
of inherited connective tissue diseases that cause blisters in the skin and mucosal membranes, with
an incidence of 20 per million newborns in the United States.
About Farmamondo: Farmamondo is a Swiss-based pharmaceutical company with a focus on
providing patient access to their unmet medical need via Early-access, Named-patient and
Compassionate-use programs. Our global footprint includes commercial operations in more
than 50 markets, headquartered from Switzerland with regional hubs in Europe, Asia and